Relay Therapeutics will present initial clinical data for its lead PI3Kα inhibitor, zovegalisib (RLY‑2608), at the International Society for the Study of Vascular Anomalies (ISSVA) World Congress 2026 in Philadelphia on May 20 and May 22. The presentation will be a late‑breaking abstract titled “Initial Results of Zovegalisib (RLY‑2608), a Mutant‑selective PI3Kα Inhibitor in Adult and Pediatric Patients with PIK3CA‑Driven Vascular Malformations.”
The data will come from about 20 efficacy‑evaluable patients, both adults and children, and will include preclinical evidence of lesion regression in mouse models. This marks a strategic expansion of zovegalisib beyond its Phase 3 breast‑cancer program (ReDiscover‑2) and leverages the drug’s unique allosteric, pan‑mutant, isoform‑selective mechanism that targets mutant PI3Kα while sparing wild‑type enzyme.
Relay’s pipeline is supported by a strong cash position of $554.5 million as of December 31 2025, which the company expects to sustain operations through 2029. The company also received FDA Breakthrough Therapy designation for zovegalisib in HR+/HER2‑negative metastatic breast cancer, underscoring its potential to address unmet needs in both oncology and vascular anomaly indications.
The presentation is expected to reach an audience of researchers and clinicians who specialize in vascular anomalies, a population estimated at 170,000 in the United States. Positive reception could accelerate future clinical development plans and enhance Relay’s competitive positioning against other PI3Kα and vascular‑anomaly therapies.
After the sessions, Relay will publish the abstract and detailed data on its website, providing stakeholders with timely insight into the drug’s clinical trajectory.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.